CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

NCT00013806 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

NIH

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: 131I-MIBG

Sponsor

National Center for Research Resources (NCRR)